A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease
about
Brief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseRecent vaccine development for human metapneumovirusApplication of Traditional Chinese Medical Herbs in Prevention and Treatment of Respiratory Syncytial VirusInduction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine.Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infectionRespiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathologyNanoemulsion-based mucosal adjuvant induces apoptosis in human epithelial cells.Nanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells.Respiratory nanoparticle-based vaccines and challenges associated with animal models and translationInnate immune sensing of HIV-1 by dendritic cells.Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.Targeting RSV with vaccines and small molecule drugs.Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.IL-17E (IL-25) and IL-17RB promote respiratory syncytial virus-induced pulmonary diseaseImmunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignThe role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.Respiratory syncytial virus--a comprehensive review.Applications of nanotechnology for immunology.Advances in and the potential of vaccines for respiratory syncytial virus.The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection.Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.Factors Affecting the Immunity to Respiratory Syncytial Virus: From Epigenetics to Microbiome.
P2860
Q26775152-77B04060-26D0-487E-BB3C-D78335956C63Q27023742-ECC87112-7D75-4F9E-8FE7-F645C5B5C873Q28076604-F21FE6F5-9B71-4226-B134-452DE832AFE9Q30382453-E4A0E062-DC8C-4052-AA17-28D99778BA4BQ34033869-9BC8BF72-B256-42FA-AD5F-9D1D313E2BE1Q34824525-6D9AB88A-18D3-4EEC-B103-BE5EEF31AF04Q35099663-DA21FAF7-17B9-43A7-B6FC-DC8B742CA95BQ35434746-29C28553-0E55-4647-83EA-1B107A9BF896Q36565552-09228A3E-C11A-471F-8126-8F77528FBFBAQ36598433-911B209F-9597-49DC-9639-E12040197211Q36748027-2F27D144-398E-4C29-961C-2A0A6C7F5214Q37130834-22A3DA12-CBBF-4ADD-A56A-F1500EFA7A3DQ37197103-D748603A-6B26-4492-B305-8C7E0D289738Q37320191-E0A15858-A4CC-45F7-9C02-B25725580CC4Q37328584-688C4351-52FD-4832-B496-31D9E388358BQ37412509-A298D431-E779-4D3F-9B1A-911896AED006Q37700171-422E222B-449E-4310-B255-A2F4EDD2FB94Q37729137-1B491A57-F620-481E-BE09-B0D149E9B4F5Q38068469-DD4497C0-82FE-4F69-8160-97404260C574Q38098094-D88BDA9A-2A90-45D5-9621-CCBCCBE31259Q38123937-8627DBE2-50D3-47EE-814F-0192490327EEQ38130514-7D4297E0-8EDF-4B1B-A685-B37C025FECA1Q38696909-E61102BF-173E-44E3-985F-D662F14722D9Q42724005-F7CB9C64-6D0B-4EDB-914A-CAEA8EECEA36Q54260283-B3DA9C79-AE6B-4C48-A9E1-DE0838F9ADAF
P2860
A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@ast
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@en
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@en-gb
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@nl
type
label
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@ast
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@en
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@en-gb
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@nl
altLabel
A Novel Inactivated Intranasal ...... iated Vaccine-Enhanced Disease
@en
prefLabel
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@ast
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@en
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@en-gb
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@nl
P2093
P2860
P3181
P1433
P1476
A novel inactivated intranasal ...... iated vaccine-enhanced disease
@en
P2093
Dennis M Lindell
James R Baker
Lara E Kallal
Maria P White
Nicholas W Lukacs
Phillip K Lundy
Susan B Morris
Tarek Hamouda
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0021823
P407
P577
2011-01-01T00:00:00Z